HK1031399A1 - Process for synthesizing cox-2 inhibitors. - Google Patents
Process for synthesizing cox-2 inhibitors.Info
- Publication number
- HK1031399A1 HK1031399A1 HK01102195A HK01102195A HK1031399A1 HK 1031399 A1 HK1031399 A1 HK 1031399A1 HK 01102195 A HK01102195 A HK 01102195A HK 01102195 A HK01102195 A HK 01102195A HK 1031399 A1 HK1031399 A1 HK 1031399A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibitors
- cox
- synthesizing
- synthesizing cox
- Prior art date
Links
- 229940111134 coxibs Drugs 0.000 title 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title 1
- 230000002194 synthesizing effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/30—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having nitrogen atoms of imino groups quaternised
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8288898P | 1998-04-24 | 1998-04-24 | |
US8566898P | 1998-05-15 | 1998-05-15 | |
PCT/US1999/008645 WO1999055830A2 (en) | 1998-04-24 | 1999-04-20 | Process for synthesizing cox-2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1031399A1 true HK1031399A1 (en) | 2001-06-15 |
Family
ID=26767964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK01102195A HK1031399A1 (en) | 1998-04-24 | 2001-03-26 | Process for synthesizing cox-2 inhibitors. |
Country Status (28)
Country | Link |
---|---|
US (2) | US6040319A (pt) |
EP (1) | EP1071745B1 (pt) |
JP (2) | JP3325264B2 (pt) |
KR (1) | KR100414998B1 (pt) |
CN (1) | CN1178658C (pt) |
AR (1) | AR015279A1 (pt) |
AT (1) | ATE272613T1 (pt) |
AU (1) | AU759469B2 (pt) |
BR (2) | BRPI9917739B8 (pt) |
CA (1) | CA2329193C (pt) |
CZ (1) | CZ292515B6 (pt) |
DE (1) | DE69919151T2 (pt) |
DK (1) | DK1071745T3 (pt) |
EA (1) | EA002975B1 (pt) |
ES (1) | ES2226378T3 (pt) |
HK (1) | HK1031399A1 (pt) |
HR (1) | HRP20000722B1 (pt) |
HU (1) | HU227627B1 (pt) |
IL (2) | IL139127A0 (pt) |
NZ (1) | NZ507597A (pt) |
PL (1) | PL193248B1 (pt) |
PT (1) | PT1071745E (pt) |
RS (1) | RS49945B (pt) |
SI (1) | SI1071745T1 (pt) |
SK (1) | SK284805B6 (pt) |
TW (1) | TW474934B (pt) |
UA (1) | UA57143C2 (pt) |
WO (1) | WO1999055830A2 (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861419A (en) * | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
MXPA01007169A (es) | 1999-01-14 | 2003-06-06 | Lonza Ag | 1-(6-metilpiridin-3-il)-2-(4-(metilsulfonil)fenil)etanona y metodo para su elaboracion. |
DE50009312D1 (de) * | 1999-01-14 | 2005-02-24 | Lonza Ag | Verfahren zur Herstellung von 1-(6-Methylpyridin-3-yl)-2-[4-(methylsulfonyl)-phenyl]ethanon |
JP2001115963A (ja) | 1999-10-13 | 2001-04-27 | Daikin Ind Ltd | 圧縮機 |
US6858631B1 (en) | 1999-11-29 | 2005-02-22 | Merck & Co., Inc. | Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl |
ES2259295T3 (es) | 1999-11-29 | 2006-10-01 | Merck Frosst Canada Inc. | Formas polimorficas, amorfas e hidratadas de 5-cloro-3-(4-metanosulfonilfenil)-6'-metil-(2,3')bipiridinilo. |
SK12672001A3 (sk) * | 1999-12-08 | 2002-04-04 | Pharmacia Corporation | Zloženia inhibítora cyklooxygenázy-2 s rýchlym nástupom terapeutického účinku |
JP2001261653A (ja) * | 2000-03-17 | 2001-09-26 | Sankio Chemical Co Ltd | ピリジン誘導体の合成法 |
US6521642B2 (en) | 2000-05-26 | 2003-02-18 | Merck & Co., Inc. | 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis |
US6800647B2 (en) | 2000-05-26 | 2004-10-05 | Merck & Co., Inc. | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis |
PH12001001175B1 (en) * | 2000-05-26 | 2006-08-10 | Merck Sharp & Dohme | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis |
CA2414674A1 (en) * | 2000-07-13 | 2002-01-24 | Pharmacia Corporation | Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders |
PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
PE20021017A1 (es) | 2001-04-03 | 2002-11-24 | Pharmacia Corp | Composicion parenteral reconstituible |
CA2445502A1 (en) * | 2001-05-04 | 2002-11-14 | Merck & Co., Inc. | Method and compositions for treating migraines |
UA80682C2 (en) * | 2001-08-06 | 2007-10-25 | Pharmacia Corp | Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition |
JP4700916B2 (ja) * | 2004-02-02 | 2011-06-15 | 富士フイルムファインケミカルズ株式会社 | ピリジン誘導体の製造方法 |
US7271383B2 (en) * | 2004-08-11 | 2007-09-18 | Lexmark International, Inc. | Scanning system with feedback for a MEMS oscillating scanner |
EP1784179A4 (en) | 2004-08-24 | 2010-03-31 | Merck Sharp & Dohme | COMBINATION THERAPY FOR THE TREATMENT OF CYCLOOXYGENASE-2-MEDIATED DISEASES OR CONDITIONS IN PATIENTS WITH RISK TO THROMBOTIC CARDIOVASCULAR EVENTS |
JP2010516679A (ja) * | 2007-01-19 | 2010-05-20 | マリンクロット インコーポレイテッド | 診断用および治療用シクロオキシゲナーゼ−2結合リガンド |
MY163020A (en) | 2009-02-27 | 2017-07-31 | Cadila Healthcare Ltd | A process for the preparation of etoricoxib |
WO2011158250A1 (en) | 2010-06-16 | 2011-12-22 | Glenmark Generics Limited | Process for preparation of 2, 3-diaryl-5-substituted pyridines and their intermediates |
MY163379A (en) | 2010-11-15 | 2017-09-15 | Virdev Intermediates Pvt Ltd | A process for cyclooxygenase-2 selective inhibitor |
ITMI20110362A1 (it) | 2011-03-09 | 2012-09-10 | F I S Fabbrica Italiana Sint P A | Procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib. |
WO2012163839A1 (en) | 2011-05-27 | 2012-12-06 | Farma Grs, D.O.O. | A process for the preparation of polymorphic form i of etoricoxib |
ITMI20111455A1 (it) | 2011-07-29 | 2013-01-30 | Italiana Sint Spa | Nuovo procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib. |
CN103204803A (zh) | 2012-01-13 | 2013-07-17 | 阿尔弗雷德·E·蒂芬巴赫尔有限责任两合公司 | 用于合成依托考昔的方法 |
ITMI20120394A1 (it) | 2012-03-14 | 2013-09-15 | Zach System Spa | Processo di sintesi di un chetosolfone derivato |
WO2013144977A2 (en) | 2012-03-30 | 2013-10-03 | Mylan Laboratories Ltd. | An improved process for the preparation of etoricoxib |
GR1007973B (el) * | 2012-06-26 | 2013-09-12 | Φαρματεν Αβεε, | Νεα ν-οξοιμινο παραγωγα ως ενδιαμεσα μιας βελτιωμενης μεθοδου παρασκευης 2,3-διαρυλο-5-υποκατεστημενων πυριδινων |
PL2887924T3 (pl) | 2012-08-27 | 2017-09-29 | Cadila Healthcare Limited | Kompozycje farmaceutyczne etorykoksybu |
ITVI20130014A1 (it) | 2013-01-22 | 2014-07-23 | Italiana Sint Spa | Procedimento molto efficiente per preparare un intermedio di etoricoxib |
WO2014114352A1 (en) * | 2013-01-25 | 2014-07-31 | Synthon Bv | Process for making etoricoxib |
CN104418799A (zh) * | 2013-09-03 | 2015-03-18 | 天津药物研究院 | 一种依托考昔的晶型及其制备方法和应用 |
WO2015036550A1 (en) | 2013-09-13 | 2015-03-19 | Synthon B.V. | Process for making etoricoxib |
US10500178B2 (en) | 2015-03-13 | 2019-12-10 | The Board Of Trustees Of The Leland Stanford Junior University | LTB4 inhibition to prevent and treat human lymphedema |
CN104817473A (zh) * | 2015-03-27 | 2015-08-05 | 南京大学 | 1-二甲氨基-3-二甲亚胺基-2-氯丙烯高氯酸盐在制备依托考昔中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA988522A (en) * | 1972-05-05 | 1976-05-04 | Haydn W.R. Williams | 1,8-naphthyridine compounds |
DE3842062A1 (de) * | 1988-12-14 | 1990-06-28 | Hoechst Ag | Explosionssichere 1-dimethylamino-3-dimethylimino-2-arylpropen-1-salze, verfahren zu ihrer herstellung und ihre verwendung |
US5861419A (en) * | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
DK0912518T3 (da) * | 1996-07-18 | 2003-12-08 | Merck Frosst Canada Inc | Substituerede pyridiner som selektive cyclooxygenase-2 inhibitorer |
-
1999
- 1999-04-20 CA CA002329193A patent/CA2329193C/en not_active Expired - Lifetime
- 1999-04-20 CZ CZ20003940A patent/CZ292515B6/cs not_active IP Right Cessation
- 1999-04-20 NZ NZ507597A patent/NZ507597A/xx not_active IP Right Cessation
- 1999-04-20 BR BRPI9917739A patent/BRPI9917739B8/pt not_active IP Right Cessation
- 1999-04-20 WO PCT/US1999/008645 patent/WO1999055830A2/en active IP Right Grant
- 1999-04-20 DK DK99918706T patent/DK1071745T3/da active
- 1999-04-20 IL IL13912799A patent/IL139127A0/xx active IP Right Grant
- 1999-04-20 KR KR10-2000-7011764A patent/KR100414998B1/ko active Protection Beyond IP Right Term
- 1999-04-20 JP JP2000545976A patent/JP3325264B2/ja not_active Expired - Lifetime
- 1999-04-20 SK SK1589-2000A patent/SK284805B6/sk not_active IP Right Cessation
- 1999-04-20 EA EA200001102A patent/EA002975B1/ru not_active IP Right Cessation
- 1999-04-20 AT AT99918706T patent/ATE272613T1/de active
- 1999-04-20 BR BRPI9909844-0A patent/BR9909844B1/pt not_active IP Right Cessation
- 1999-04-20 PT PT99918706T patent/PT1071745E/pt unknown
- 1999-04-20 UA UA2000116652A patent/UA57143C2/uk unknown
- 1999-04-20 PL PL344108A patent/PL193248B1/pl unknown
- 1999-04-20 DE DE69919151T patent/DE69919151T2/de not_active Expired - Lifetime
- 1999-04-20 SI SI9930632T patent/SI1071745T1/xx unknown
- 1999-04-20 EP EP99918706A patent/EP1071745B1/en not_active Expired - Lifetime
- 1999-04-20 ES ES99918706T patent/ES2226378T3/es not_active Expired - Lifetime
- 1999-04-20 HU HU0101407A patent/HU227627B1/hu unknown
- 1999-04-20 AU AU36557/99A patent/AU759469B2/en not_active Expired
- 1999-04-20 CN CNB998075507A patent/CN1178658C/zh not_active Expired - Lifetime
- 1999-04-20 RS YUP-641/00A patent/RS49945B/sr unknown
- 1999-04-23 US US09/298,127 patent/US6040319A/en not_active Expired - Lifetime
- 1999-04-23 AR ARP990101884A patent/AR015279A1/es active IP Right Grant
- 1999-04-23 TW TW088106545A patent/TW474934B/zh active
-
2000
- 2000-01-21 US US09/488,774 patent/US6252116B1/en not_active Expired - Fee Related
- 2000-10-18 IL IL139127A patent/IL139127A/en not_active IP Right Cessation
- 2000-10-24 HR HR20000722A patent/HRP20000722B1/xx not_active IP Right Cessation
-
2001
- 2001-03-26 HK HK01102195A patent/HK1031399A1/xx not_active IP Right Cessation
-
2002
- 2002-05-22 JP JP2002147700A patent/JP3834263B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1031399A1 (en) | Process for synthesizing cox-2 inhibitors. | |
HK1039487A1 (en) | Process for the synthesis of azetidinones. | |
ZA997866B (en) | Method for providing refrigeration. | |
HK1041407A1 (en) | Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors. | |
ZA200203293B (en) | Method for synthesizing the nucleic acid. | |
ZA991975B (en) | Enzyme inhibitors. | |
ZA200001333B (en) | Method for communicating information. | |
AU3077699A (en) | Apparatus for performing hippotherapy | |
IL138821A (en) | Method for unambigous range estimation | |
AU5660399A (en) | An apparatus for performing animal related operations | |
GB9819417D0 (en) | Reaction method | |
HK1052702A1 (en) | Method for the preparation of 5-carboxyphthalide. | |
AU3444899A (en) | Method for the rapid determination of bacteria | |
EP1059760A4 (en) | BLOCK ENCRYPTION OF DISCRETE DATA | |
AU5867901A (en) | Method for detecting tumors | |
AU3583000A (en) | Method for direct steelmaking | |
AU5041099A (en) | Hydroformylation process | |
MX225445B (es) | Metodo y produccion de n-fosfonometilglicina. | |
HUP9901733A3 (en) | Method for transmitting data | |
AU1810399A (en) | Method for synthesizing | |
HK1044780A1 (en) | Method for producing cyclo-)asp-dphe-nmeval-arg-gly). | |
HUP0102016A3 (en) | Method for copperplating substrates | |
HUP0103002A3 (en) | New process for obtaining 17betha-(n-terc-butylcarbamoyl)-3-one-4-aza-steroids | |
AU7105800A (en) | Process for synthesizing isoxazolidines | |
ZA200104182B (en) | Process for preparing trichloroalkane derivatives. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20140420 |